Kymera Therapeutics, Inc. insider trading

In twelve months insiders at Kymera Therapeutics bought $172M and sold $467M on the open market; 221 of the 263 sales were under plans set months before.

Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.

The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.

A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.

One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.

The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.